Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFrontier Ip Regulatory News (FIPP)

Share Price Information for Frontier Ip (FIPP)

Share Price is delayed by 15 minutes
Get Live Data
15.75    0.00 (0.00%)
Bid:
15.50
Ask:
16.00
Spread: 0.50 (3.226%)
Market Cap: £13.00m
FIPP Live PriceLast checked at - London Stock Exchange

Intraday Frontier Ip Share Chart

Portfolio Company - Tate & Lyle Contract

11 Dec 2012 07:00

RNS Number : 1970T
Frontier IP Group plc
11 December 2012
 



 

 

 

 

 

AIM: FIPP

 

 

FRONTIER IP GROUP PLC

("Frontier IP" or "the Group")

 

Portfolio company signs licence agreement with Tate & Lyle

 

Frontier IP, which specialises in the commercialisation of intellectual property, is pleased to announce that its portfolio company, Nandi Proteins Limited ("Nandi"), has concluded a licence agreement for the use of its innovative protein technology with Tate & Lyle PLC ("Tate & Lyle"), the global provider of ingredients and solutions to the food and beverage sectors. As reported on 6 November 2012, the conclusion of these licence terms will result in the payment of advisory fees to Frontier IP and is expected to result in an uplift in the valuation of Frontier IP's holding in Nandi, which is a spin-out company from Heriot Watt University in Edinburgh.

 

The agreement grants Tate & Lyle an exclusive worldwide licence to use aspects of Nandi's protein technology for food and beverage applications. Tate & Lyle will be responsible for developing the technology further for new food and beverage ingredients primarily relating to its texturant portfolio.

 

Nandi's protein technology has wide-ranging application in the food sector and potentially beyond. The technology improves the functional properties of common proteins and in food and beverage applications can boost the textural attributes, or 'mouthfeel', of certain food products.

 

Neil Crabb, Chief Executive, commented,

 

"I am delighted to report that our portfolio company, Nandi, has concluded its licence agreement with Tate & Lyle. Tate & Lyle look for innovations that will lead to exciting new food and beverage ingredients and Nandi's technology offers this. The agreement also reflects Nandi's strategy of developing partnerships with major industry players, which continues."

 

 

 

Enquiries

Company website: www.frontierip.co.uk

 

Frontier IP Group Plc

T: 0131 220 9491

Neil Crabb, Chief Executive

Seymour Pierce Ltd (Nominated Adviser and Joint Broker)

T: 020 7107 8000

Guy Peters / Julian Erleigh - Corporate Finance

David Banks / Paul Jewell - Corporate Broking

Peterhouse Corporate Finance Limited (Joint Broker)

T: 020 7469 0935

Jon Levinson / Lucy Williams

Biddicks

T: 020 3178 6378

Katie Tzouliadis

 

 

 

 

 

 

Notes to Editor:

 

Frontier IP Group Plc ("Frontier IP")specialises in the commercialisation of Intellectual Property. It establishes partnerships with individual universities and research institutions to assist with their spin-out and licensing activities and helps to maximise the commercial value of technologies emerging from their research programmes.

 

Nandi Proteins Limited ("Nandi") is a sales, marketing, IP and licensing company spun out of Heriot Watt University, Edinburgh in 2001. The company was established to exploit patented process technology and know how to improve the functional properties of common proteins such as whey, egg and soy. The company's objective is to become a market leader in the field of denatured protein technology. Denatured egg and dairy proteins are currently being produced on a factory scale and have been successfully used in applications by major companies in the food industry.

Tate & Lyle PLC ("Tate & Lyle") is a global provider of ingredients and solutions to the food, beverage and other industries, operating from over 30 production facilities around the world. Tate & Lyle operates through two global business units, Speciality Food Ingredients and Bulk Ingredients, supported by Innovation and Commercial Development. The Group's strategy is to become the leading global provider of Speciality Food Ingredients through a disciplined focus on growth, and by driving the Bulk Ingredients business for sustained cash generation to fuel this growth.

Speciality Food Ingredients include starch-based speciality ingredients (corn-based speciality starches, sweeteners and fibres), no calorie sweeteners (including SPLENDA® Sucralose) and Food Systems which provides blended ingredient solutions. Bulk Ingredients include corn-based bulk sweeteners, industrial starches and fermentation products (primarily acidulants). The co-products from both divisions are primarily sold as animal feed.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCZMMMZRGNGZZM
Date   Source Headline
6th Jul 20267:00 amRNS-RInSignals Neurotech Grant
30th Jun 20265:00 pmRNSTotal Voting Rights
26th Jun 202610:03 amRNSHolding(s) in Company
25th Jun 20262:44 pmRNSHolding(s) in Company
25th Jun 20267:00 amRNSHolding(s) in Company
24th Jun 20267:00 amRNS-RPortfolio news: Investment in Fieldwork Robotics
23rd Jun 20267:00 amRNSPosting of Circular and Notice of General Meeting
19th Jun 20267:00 amRNSResult of Retail Offer
17th Jun 20267:00 amRNSResult of Placing and Subscription
16th Jun 20265:20 pmRNSRetail Offer
16th Jun 20264:58 pmRNSProposed Placing and Subscription
26th May 20267:00 amRNS-RPortfolio news: Dekiln strategic partnership
5th May 20267:00 amRNSAppointment of Chief Financial Officer
16th Apr 20264:07 pmRNSHolding(s) in Company
15th Apr 20267:00 amRNSPortfolio News: 2D Photonics subsidiary grant
13th Apr 20262:35 pmRNSHolding(s) in Company
10th Apr 202610:30 amRNSUpdate re Investee Company
8th Apr 20267:00 amRNS-RPortfolio news – Fieldwork Robotics £3M fundraise
31st Mar 20265:18 pmRNSHolding(s) in Company
30th Mar 20267:00 amRNSUnaudited Half Year Results
23rd Mar 20267:00 amRNS-RAlusid reaches milestone in European roll out
28th Jan 20264:28 pmRNSHolding(s) in Company
19th Jan 20267:00 amRNS-RPortfolio news - Strong results for TVG vaccine
12th Jan 202610:30 amRNSHolding(s) in Company
31st Dec 20251:00 pmRNSTotal Voting Rights
31st Dec 20251:00 pmRNSTotal Voting Rights
31st Dec 202512:30 pmRNSResult of AGM
31st Dec 202512:30 pmRNSResult of AGM
29th Dec 20252:37 pmRNSHolding(s) in Company
29th Dec 20252:37 pmRNSHolding(s) in Company
24th Dec 20259:52 amRNSHolding(s) in Company
24th Dec 20259:52 amRNSHolding(s) in Company
24th Dec 20257:00 amRNSHolding(s) in Company
23rd Dec 20252:17 pmRNSDirectors' Shareholdings
23rd Dec 20252:17 pmRNSDirectors’ Shareholdings
22nd Dec 20253:48 pmRNSResult of Retail Offer
22nd Dec 20253:48 pmRNSResult of Retail Offer
18th Dec 20259:15 amRNS-RDekiln benefits from £3 million funding
17th Dec 202511:54 amRNSResult of Placing and Subscription
17th Dec 20257:01 amRNSRetail Offer
17th Dec 20257:00 amRNSProposed Placing and Subscription to raise £870k
15th Dec 20257:00 amRNS-RPortfolio news- Alusid £500k pre-IPO funding round
10th Dec 20254:56 pmRNSHolding(s) in Company
9th Dec 20257:00 amRNSPosting of Annual Report & Notice of AGM
8th Dec 20257:00 amRNSFinal results for the year ended 30 June 2025
2nd Dec 20257:00 amRNS-RAlusid signs Swedish distribution agreement
6th Nov 20257:00 amRNSBord Change
3rd Nov 20257:00 amRNS-RTVG demonstrates success in animal trials
20th Oct 20257:00 amRNS-RAmprologix raises £740,000 in Pre-Series A round
25th Sep 20257:00 amRNSBoard Changes

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.